Compare Nucor Corporation (NUE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Nucor Corporation trades at $258 (market cap $58.51B), while State Street SPDR S&P Biotech ETF trades at $159.61. The key difference: Nucor Corporation pays a 0.87% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| NUE | XBI | |
|---|---|---|
Market Cap | $58.51B | — |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $274.74 | $169.55 |
52-Week Low | $131.78 | $93.43 |
Enterprise Value | $62.92B | — |
Dividend Yield | 0.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $256.4, down 1.79% on the day, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 and Q2 2026, and the stock benefits from positive sentiment around U.S. steel demand and tariff protections. The company maintains solid profitability with a net margin of 7.99% and ROE of 13.52%, though revenue has moderated from 2022 peaks.
Outlook is positive with a consensus price target of $281.38, implying ~10% upside. Key opportunities include infrastructure demand and new capacity, while risks involve cyclical steel industry pressures and volatile cash flows. Institutional buying, like CalSTRS' increased stake, supports confidence.
XBI (SPDR S&P Biotech ETF) trades at $161.97, down 1.12% on the day, with a bearish technical signal overall despite bullish moving averages. The ETF holds over 150 biotech companies, benefiting from strong M&A activity and positive clinical catalysts, though key financial ratios are not applicable for the fund structure. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic given sector tailwinds, but high volatility and concentration in small-cap biotech pose risks. The single analyst covering the ETF maintains a Hold rating, reflecting a neutral stance amid the sector's rally and inherent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
